Literature DB >> 8827524

High yield overexpression and characterization of human recombinant proapolipoprotein A-I.

K A McGuire1, W S Davidson, A Jonas.   

Abstract

Human apolipoprotein A-I (apoA-I) is the major protein component of high density lipoproteins (HDL) where it defines the particle structure and stability and functions as the main activator of the enzyme lecithin:cholesterol acyltransferase (LCAT). ApoA-I is expressed in the liver as a preproprotein that is targeted to the endoplasmic reticulum for secretion; in plasma, an unknown protease removes the six amino acid long propeptide. In this study, the cDNA coding the human proapoA-I was cloned into an Escherichia coli vector; the overexpressed protein was purified to 99% homogeneity and was extensively characterized together with mature apoA-I purified from plasma. SDS-PAGE, mass spectrometry, and Edman sequence analysis showed that the initial Met residue needed for translation in E. coli is posttranslationally removed from the N-terminal sequence of the proapoA-I. The structural and functional analyses were carried out on the lipid-free and the lipid-bound proteins. ProapoA-I self associated, interacted with dimyristoyl phosphatidylcholine vesicles, and formed secondary structures very similar to the lipid-free apoA-I. Reconstituted HDL particles made with two initial molar ratios of palmitoyloleoyl phosphatidylcholine/cholesterol/apolipoprotein/Na-cholate had identical particle sizes and distributions when apoA-I or proapoA-I were used. Particles having diameters of 79 A and 98 A, containing two apoA-I or proapoA-I molecules per particle, were isolated and characterized. The particles contained the same amounts of alpha-helical structure, had very similar fluorescence properties, and activated LCAT equally well. We conclude that proapoA-I expressed and purified from E. coli is functionally and structurally indistinguishable from mature apoA-I purified from plasma when analyzed in vitro. Therefore, this recombinant proapoA-I and mutants derived from it will be important sources of protein for analyzing apoA-I structure and function, as well as for studies of proapoA-I processing.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827524

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  7 in total

1.  Cubbing in proapolipoprotein maturation.

Authors:  Godfrey S Getz; Catherine A Reardon
Journal:  J Lipid Res       Date:  2011-09-06       Impact factor: 5.922

2.  Predicting the structure of apolipoprotein A-I in reconstituted high-density lipoprotein disks.

Authors:  J C Phillips; W Wriggers; Z Li; A Jonas; K Schulten
Journal:  Biophys J       Date:  1997-11       Impact factor: 4.033

3.  Disruption of the murine procollagen C-proteinase enhancer 2 gene causes accumulation of pro-apoA-I and increased HDL levels.

Authors:  Omar L Francone; Brian Y Ishida; Margarita de la Llera-Moya; Lori Royer; Christiane Happe; Jian Zhu; Robert J Chalkey; Peter Schaefer; Cheryl Cox; Al Burlingame; John P Kane; George H Rothblat
Journal:  J Lipid Res       Date:  2011-07-19       Impact factor: 5.922

4.  A gel-based method for purification of apolipoprotein A-I from small volumes of plasma.

Authors:  Rachel J Brace; Brie Sorrenson; Dmitri Sviridov; Sally P A McCormick
Journal:  J Lipid Res       Date:  2010-07-27       Impact factor: 5.922

5.  Regulation of apoAI processing by procollagen C-proteinase enhancer-2 and bone morphogenetic protein-1.

Authors:  Jian Zhu; Joseph Gardner; Clive R Pullinger; John P Kane; John F Thompson; Omar L Francone
Journal:  J Lipid Res       Date:  2009-02-23       Impact factor: 5.922

Review 6.  The unsolved mystery of apoA-I recycling in adipocyte.

Authors:  Shuai Wang; Dao-quan Peng; Yuhong Yi
Journal:  Lipids Health Dis       Date:  2016-02-24       Impact factor: 3.876

7.  Effect of Lipid Composition on the Atheroprotective Properties of HDL-Mimicking Micelles.

Authors:  Kristen Hong; Minzhi Yu; Julia Crowther; Ling Mei; Karl Olsen; Yonghong Luo; Yuqing Eugene Chen; Yanhong Guo; Anna Schwendeman
Journal:  Pharmaceutics       Date:  2022-07-28       Impact factor: 6.525

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.